David Cohen

A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3

P. Marcellin, K. Chayama, Sheng-Nan Lu, 2016, SpringerPlus.

1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS

G. Everson, K. Kowdley, E. Lawitz, 2012 .

Randomized Study of Asunaprevir plus Pegylated Interferon-α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C

K. Reddy, P. Thuluvath, S. Pol, 2013, Antiviral therapy.

1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY

G. Dore, S. Pol, A. Tran, 2013 .

Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B).

P. Marcellin, C. Coffin, S. Zeuzem, 2016, Journal of hepatology.

High rates of viral suppression after long-term entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B.

Ching-lung Lai, Hong Tang, K. Kowdley, 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

BRIEF COMMUNICATIONS High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B

Hong Tang, K. Kowdley, S. Yoon, 2012 .

Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.

Huy Trinh, A. Lok, U. Akarca, 2012, Gastroenterology.

1187 ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12) AND SAFETY RESULTS

T. Pilot‐Matias, K. Kowdley, W. Xie, 2012 .

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.

P. Thuluvath, S. Pol, V. Ratziu, 2014, Journal of hepatology.

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.

V. de Lédinghen, G. Dore, S. Pol, 2015, Gastroenterology.

P1230 LACK OF IMPACT OF BASELINE RESISTANCE-ASSOCIATED VARIANTS (RAVS) ON TREATMENT OUTCOME IN THE AVIATOR STUDY WITH ABT-450/R, ABT-333 AND ABT-267, +/– RIBAVIRIN

T. Pilot‐Matias, T. Reisch, W. Xie, 2014 .